Psychiatry and Neurology, Neurology · Golden Valley, MN
NPI
1194765388
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
4225 Golden Valley Rd
Golden Valley, MN, 55422
Phone (763) 302-4199
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
75,856 services
Medicare patients, 2024
261
Average age 66
Drug cost, 2024
$2.8M
1,590 prescriptions
Company payments, 2025
$42K
From 15 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jonathan C Calkwood was code J2350 (injection, ocrelizumab, 1 mg), 12,600 times for 20 patients. In total Jonathan C Calkwood billed 75,856 services in 68 codes, and Medicare paid $1.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-05-17.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2350 Injection, ocrelizumab, 1 mg | Office | 12,600 | 20 | $46.57 | $587K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 6,320 | 16 | $35.51 | $224K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 5,750 | 22 | $35.81 | $206K |
| J0897 Injection, denosumab, 1 mg | Office | 720 | 12 | $20.75 | $15K |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 479 | 18 | $0.23 | $108 |
| 96366 Intravenous Infusion, Hydration | Office | 256 | 43 | $16.12 | $4,126 |
| 96365 Intravenous Infusion, Hydration | Office | 192 | 61 | $48.64 | $9,339 |
| 96375 Injection Administration | Office | 126 | 48 | $11.90 | $1,499 |
| J1720 Injection, hydrocortisone sodium succinate, up to 100 mg | Office | 99 | 27 | $14.54 | $1,439 |
| 99215 Office E&M - Established | Office | 99 | 89 | $126.68 | $13K |
| 96372 Injection Administration | Office | 93 | 35 | $11.17 | $1,039 |
| 92133 Computerized Ophthalmic Imaging | Office | 92 | 83 | $26.75 | $2,461 |
| 96413 Chemotherapy Administration | Office | 77 | 45 | $97.87 | $7,536 |
| 96415 Chemotherapy Administration | Office | 49 | 27 | $20.96 | $1,027 |
| 99214 Office E&M - Established | Office | 43 | 42 | $91.70 | $3,943 |
By year: 2022 $2.2M for 74,049 services; 2023 $2.0M for 76,538 services; 2024 $1.7M for 75,856 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 40 | 37 | $8.22 | $329 |
Medicare prescription drug claims, 2024
In 2024, the drug Jonathan C Calkwood prescribed most often to Medicare patients was Baclofen, with 286 prescriptions and refills. In total Jonathan C Calkwood wrote 1,590 Medicare prescriptions that cost $2.8M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Baclofen Generic | 286 | 530 | 74 | $11K |
| Gabapentin Generic | 123 | 235 | 31 | $2,810 |
| Dalfampridine Er Dalfampridine | 93 | 190 | 20 | $35K |
| Tizanidine Hcl Generic | 87 | 127 | 15 | $1,722 |
| Dimethyl Fumarate Generic | 64 | 78 | Under 11 | $18K |
| Betaseron Interferon Beta-1b | 60 | 61 | Under 11 | $585K |
| Copaxone Glatiramer Acetate | 56 | 56 | Under 11 | $327K |
| Valacyclovir Valacyclovir Hcl | 56 | 130 | 13 | $2,826 |
| Trazodone Hcl Generic | 42 | 80 | 13 | $624 |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 42 | 78 | 13 | $1,674 |
| Oxybutynin Chloride Er Oxybutynin Chloride | 30 | 38 | Under 11 | $707 |
| Levetiracetam Generic | 29 | 51 | Under 11 | $982 |
| Amantadine Amantadine Hcl | 29 | 55 | Under 11 | $838 |
| Teriflunomide Generic | 28 | 34 | Under 11 | $46K |
| Glatiramer Acetate Generic | 27 | 27 | Under 11 | $77K |
Brand drugs: 266 claims; generic drugs: 1,324 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jonathan C Calkwood $42K ($42K in general payments such as food, travel and fees) from 15 companies. The largest payer was TG Therapeutics, Inc. with $25K.
| Company | Payments | Amount |
|---|---|---|
| TG Therapeutics, Inc. TGTX | 14 | $25K |
| Biogen, Inc. BIIB | 5 | $8,810 |
| Genentech USA, Inc. ROG.SW | 8 | $7,704 |
| Lundbeck LLC | 2 | $33.04 |
| Cycle Pharmaceuticals Inc | 1 | $28.06 |
| Alexion Pharmaceuticals, Inc. AZN | 1 | $24.57 |
| Argenx US, Inc. ARGX | 1 | $21.39 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $21.05 |
| CSL Behring CSL.AX | 1 | $18.94 |
| Amgen Inc. AMGN | 1 | $18.85 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.